With a new 5 mm diameter stent added to the Zilver PTX arsenal, Cook Medical has expanded its offering of the broadest range of drug-eluting stent (DES) sizes available to treat peripheral arterial disease (PAD) in the superficial femoral artery (SFA).1,2
The distal SFA and proximal popliteal are often smaller diameter vessels and cannot always be treated with a DES that is sized properly to the vessel. The Zilver PTX 5 mm stent now allows physicians to treat patients who have smaller vessels with a DES.3
On Jan. 10, 2019, Dr. Robert Beasley, director of Mount Sinai’s Vascular/Interventional Radiology Lab and Evanescence Vein Center, became the first U.S. physician to use a 5 mm DES. The Miami-based interventional radiologist treated a female patient with a small SFA.
The distal SFA and proximal popliteal artery extend through the Hunter’s Canal where significant stress occurs, causing a unique challenge when treating PAD.
Dr. Beasley has been using Zilver PTX since its market release in 2012. He is currently one of the highest users of Zilver PTX in the nation. “I’ve seen significantly improved primary patency rates on follow-up imaging. This benefit is confirmed on yearly follow-up examination,” he said. “When significant restenosis occurs, it is usually manifested in short focal lesions.”
Zilver PTX is the world’s first DES used to treat PAD in the SFA and the only drug-eluting SFA stent with five-year data.4 It’s indicated for improving luminal diameter for the treatment of de novo or restenotic symptomatic lesions in native vascular disease of the above-the-knee femoropopliteal arteries having reference vessel diameter from 4 mm to 7 mm and total lesion lengths up to 300 mm per patient.1
In addition to the new 5 mm stent offering, Zilver PTX is available in 6, 7, and 8 mm diameters and lengths of 40, 60, 80, 100, 120, and 140 mm.
Dr. Beasley is a paid consultant of Cook Medical.
- Refer to the Instructions for Use (IFU0118) for a clinical data overview.
- Refer to the Instructions for Use (IFU50565157-01) for a clinical data overview.
- Cipollari S, Yokoi H, Ohki T, et al. Long-term effectiveness of the Zilver PTX drug-eluting stent for femoropopliteal peripheral artery disease in patients with no patent tibial runoff vessels—results from the Zilver PTX Japan Post-Market Surveillance Study. J Vasc Interv Radiol. 2018;29(1):9-17.
- Dake MD, Ansel GM, Jaff MR, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133(15):1472-1483.